BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37075745)

  • 21. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
    McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
    Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RUVBL1/2 Complex Regulates Pro-Inflammatory Responses in Macrophages
    Zhang R; Cheung CY; Seo SU; Liu H; Pardeshi L; Wong KH; Chow LMC; Chau MP; Wang Y; Lee AR; Kwon WY; Chen S; Chan BK; Wong K; Choy RKW; Ko BCB
    Front Immunol; 2021; 12():679184. PubMed ID: 34276666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B; Ji W; Xia H; Li J
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1.
    García-Domínguez DJ; Hajji N; López-Alemany R; Sánchez-Molina S; Figuerola-Bou E; Morón Civanto FJ; Rello-Varona S; Andrés-León E; Benito A; Keun HC; Mora J; Tirado ÓM; de Álava E; Hontecillas-Prieto L
    Oncogene; 2022 Apr; 41(18):2638-2650. PubMed ID: 35354905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
    Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
    Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
    Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
    Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RUNX3 facilitates growth of Ewing sarcoma cells.
    Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
    J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein.
    Theisen ER; Selich-Anderson J; Miller KR; Tanner JM; Taslim C; Pishas KI; Sharma S; Lessnick SL
    Epigenetics; 2021 Apr; 16(4):405-424. PubMed ID: 32842875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.
    Sheffield NC; Pierron G; Klughammer J; Datlinger P; Schönegger A; Schuster M; Hadler J; Surdez D; Guillemot D; Lapouble E; Freneaux P; Champigneulle J; Bouvier R; Walder D; Ambros IM; Hutter C; Sorz E; Amaral AT; de Álava E; Schallmoser K; Strunk D; Rinner B; Liegl-Atzwanger B; Huppertz B; Leithner A; de Pinieux G; Terrier P; Laurence V; Michon J; Ladenstein R; Holter W; Windhager R; Dirksen U; Ambros PF; Delattre O; Kovar H; Bock C; Tomazou EM
    Nat Med; 2017 Mar; 23(3):386-395. PubMed ID: 28134926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Promoter-Associated Noncoding RNA
    Palombo R; Frisone P; Fidaleo M; Mercatelli N; Sette C; Paronetto MP
    Cancer Res; 2019 Jul; 79(14):3570-3582. PubMed ID: 31072811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
    Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
    BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.
    Lin L; Huang M; Shi X; Mayakonda A; Hu K; Jiang YY; Guo X; Chen L; Pang B; Doan N; Said JW; Xie J; Gery S; Cheng X; Lin Z; Li J; Berman BP; Yin D; Lin DC; Koeffler HP
    Nucleic Acids Res; 2019 Feb; 47(3):1255-1267. PubMed ID: 30496486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.